Cardiac ablation firm pulls in $5m series B
This article was originally published in Clinica
Advanced Cardiac Therapeutics (ACT) is preparing to initiate full European commercial launch of its cardiac ablation technology this year, after closing a $5m series B financing round. NBGI Ventures was the lead investor. ACT has developed an irrigated, radiofrequency cardiac ablation catheter, which incorporates a microwave radiometry technology that measures – in real time – ablation temperatures inside cardiac tissue. This gives the electrophysiologist better control when they are creating lesions with the ablation catheter, and potentially improves patient outcomes, says Laguna Beach, California-based ACT. Current irrigated cardiac ablation systems do not provide tissue temperature feedback, according to the firm.